Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Samsung Bioepis

- PMLiVE

FDA fast tracks Novartis’ SMA gene therapy

Gene therapy could be approved in first half of 2019, will challenge Biogen's Spinraza

- PMLiVE

Spinraza lifts Biogen ahead of Alzheimer’s data

Continued strong growth for Biogen’s spinal muscular atrophy therapy Spinraza helped the company exceed revenue expectations in the third quarter, but pipeline disappointments kept its shares largely static.Spinraza (nusinersen) was...

- PMLiVE

Shock as NICE turns down Biogen’s SMA therapy

UK’s cost effectiveness watchdog says the drug’s long-term benefits are unclear

Biogen Idec building

Big debate follows Biogen/Eisai’s Alzheimer’s study unveiling

Mixed results prompted a 10% share drop for both companies

- PMLiVE

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Biotech sees 9% growth ahead of potential landmark announcement

Biogen Idec building

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

Says drug slowed down progression of cognitive decline

- PMLiVE

Biogen appoints executive VP, corporate development

Daniel Karp will also become a member of the executive committee

- PMLiVE

Novartis buys gene therapy firm AveXis for $8.7bn

Lead candidate AVXS-101 could potentially replace regular drug treatment for SMA with a one-off intervention

Biogen Idec building

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Agreement could see Europe access Imraldi as early as October this year

Biogen Idec building

Biogen pays $590m for Pfizer cognition drug

Early stage studies look positive for schizophrenia drug

- PMLiVE

MSD launches EU’s first biosimilar Herceptin in UK

Ontruzant is set to be strong competition for Roche’s blockbuster

Biogen Idec building

Biogen and AbbVie pull MS drug Zinbryta from the market

Potential risks of liver damage and immune-related conditions have been reported

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links